CYTARABINE Side Effects

6816233-0 | Apnoea, Areflexia, Brain Oedema, Cardiac Arrest, Hypotension, Meningitis, Mental Status Changes
on Jul 02, 2010 Female patient from UNITED STATES , weighting 168.4 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: apnoea, areflexia, brain oedema, cardiac arrest (What is cardiac arrest?), hypotension, meningitis (What is meningitis?), mental status changes. Cytarabine dosage: 70 Mg. During the same period patient was treated with DAUNORUBICIN HCL (188 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (15 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (4700 Iu) (View Peg-l Asparaginase (k-h) Review and Peg-l Asparaginase (k-h) Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6807018-X | Acidosis, Bradycardia, Cardio-respiratory Arrest, Decubitus Ulcer, Dialysis, Hyperkalaemia, Infection, Neutropenia
Patient was taking Cytarabine (View Usage). Patient had the following side effects: acidosis, bradycardia, cardio-respiratory arrest, decubitus ulcer, dialysis (What is dialysis?), hyperkalaemia, infection (What is infection?), neutropenia on Jun 28, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 205.3 lb, . Cytarabine dosage: 3800 Mg. During the same period patient was treated with DAUNORUBICIN HCL (285 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6787710-6 | Cytarabine Syndrome
Adverse event was reported on May 24, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: Intravenous) . Location: UNITED KINGDOM , 64 years of age, After Cytarabine was administered, patient had the following side effects: cytarabine syndrome. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), COTRIM (View Cotrim Review and Cotrim Label ), TRIMETHOPRIM (View Trimethoprim Review and Trimethoprim Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ). Patient was hospitalized.

6786019-4 | Asthenia, Brain Abscess, Confusional State, Headache, Scedosporium Infection
on Jun 21, 2010 Male patient from UNITED STATES , weighting 232.6 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: asthenia, brain abscess, confusional state, headache (What is headache?), scedosporium infection. Cytarabine dosage: 70 Mg. During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (220 Mg) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), METHOTREXATE (15 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (5500 Mg) (View Peg-l-asparaginase (k-h) Review and Peg-l-asparaginase (k-h) Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.


6781493-1 | Hemiplegia, Thrombophlebitis
on Jun 09, 2010 Female patient from FRANCE , 43 years of age, was diagnosed with acute lymphocytic leukaemia, acute myeloid leukaemia and was treated with Cytarabine (View Usage). Patient had the following side effects: hemiplegia, thrombophlebitis. Cytarabine dosage: Total Dose Of 40 Mg On Day 1 And Day 8. During the same period patient was treated with DEPO MEDROL (Total Dose Of 40 Mg On D1 And D8) (View Depo-medrol Review and Depo-medrol Label ), KIDROLASE (6000 Iu/m2 On Day 8) (View Kidrolase Review and Kidrolase Label ), VINCRISTINE (2 Mg On D1, D8 Then D19, D21) (View Vincristine Review and Vincristine Label ), CERUBIDIN (50 Mg/m2 On D1, D2 And D3) (View Cerubidin Review and Cerubidin Label ), ENDOXAN (750 Mg/m2 On D1) (View Endoxan Review and Endoxan Label ), METHOTREXATE MERCK (Total Dose Of 15 Mg On D1 And D8) (View Methotrexate Merck Review and Methotrexate Merck Label ).

6781005-2 | Emphysema, Interstitial Lung Disease, Pneumocystis Jiroveci Infection, Pneumomediastinum, Pneumothorax, Respiratory Distress, Withdrawal Of Life Support
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: emphysema, interstitial lung disease, pneumocystis jiroveci infection, pneumomediastinum, pneumothorax, respiratory distress, withdrawal of life support on Jun 17, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 51.37 lb, . Cytarabine dosage: 48 Mg. During the same period patient was treated with DAUNORUBICIN HCL (42 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), DEXAMETHASONE ACETATE (200 Mg) (View Dexamethasone Acetate Review and Dexamethasone Acetate Label ), HYDROCORTISONE (24 Mg) (View Hydrocortisone Review and Hydrocortisone Label ), METHOTREXATE (24 Mg) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE SULFATE (2.6 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6776694-2 | Blood Creatine Phosphokinase Increased, Blood Creatinine Increased, Blood Culture Positive, Ejection Fraction Decreased, Electrocardiogram Qt Prolonged, Electrocardiogram St Segment Depression, Febrile Neutropenia, Staphylococcal Infection, Troponin Increased
Adverse event was reported on Jun 17, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 32160 Mg) . Location: UNITED STATES , weighting 291.0 lb, Patient experienced the following unwanted or unexpected effects: blood creatine phosphokinase increased, blood creatinine increased, blood culture positive, ejection fraction decreased, electrocardiogram qt prolonged, electrocardiogram st segment depression, febrile neutropenia, staphylococcal infection (What is staphylococcal infection?), troponin increased. During the same period patient was treated with ETOPOSIDE (3376 Mg) (View Etoposide Review and Etoposide Label ), RITUXIMAB (MOAB C2B8 ANTI CD20 CHIMERIC) (1500 Mg) (View Rituximab (moab C2b8 Anti Cd20 Chimeric) Review and Rituximab (moab C2b8 Anti Cd20 Chimeric) Label ). Patient was hospitalized.

6773624-4 | Cardiac Arrest
on Jun 09, 2010 Male patient from UNITED KINGDOM , 66 years of age, was diagnosed with leukaemia and was treated with Cytarabine (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?). Cytarabine dosage: 20 Mg Milligram(s), 2 Day, Subcutaneous. During the same period patient was treated with MYLOTARG (5 Mg Milligram(s), Intravenous) (View Mylotarg Review and Mylotarg Label ).

6765222-3 | Infusion Site Erythema, Infusion Site Pain
on Jun 10, 2010 Male patient from UNITED STATES , weighting 175.7 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: infusion site erythema, infusion site pain. Cytarabine dosage: 6090 Mg. Patient was hospitalized.

6763294-3 | Catheter Site Erythema, Catheter Site Oedema, Catheter Site Pain, Cellulitis, Lung Infiltration, Lymphadenopathy, Multi-organ Failure, Neutropenia
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: catheter site erythema, catheter site oedema, catheter site pain, cellulitis (What is cellulitis?), lung infiltration, lymphadenopathy, multi-organ failure, neutropenia on Jun 08, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 220.5 lb, . Cytarabine dosage: 4570 Mg. During the same period patient was treated with DAUNORUBICIN HCL (336 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (1125 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6761428-8 | Cytarabine Syndrome, Hypoxia, Pyrexia
Adverse event was reported on May 24, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: Intravenous) . Location: UNITED KINGDOM , 64 years of age, Patient had the following side effects: cytarabine syndrome, hypoxia, pyrexia. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), COTRIM (View Cotrim Review and Cotrim Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6761357-X | Adenoma Benign, Aphasia, Asthenia, Ataxia, Cachexia, Cardiac Failure, Cardiopulmonary Failure, Cardiotoxicity, Cytomegalovirus Infection
on May 14, 2010 Female patient from DENMARK , 53 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: adenoma benign, aphasia (What is aphasia?), asthenia, ataxia (What is ataxia?), cachexia, cardiac failure, cardiopulmonary failure, cardiotoxicity, cytomegalovirus infection (What is cytomegalovirus infection?). Cytarabine dosage: 2g/m2, Intravenous. During the same period patient was treated with CISPLATIN (100 Mg/m 2 Milligram(s) /sq. Meter, Intravenous) (View Cisplatin Review and Cisplatin Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

6760918-1 | Aspergillus Test Positive, Haemoptysis, Lung Infiltration, Neutropenia, Pulmonary Vascular Disorder, Zygomycosis
on May 20, 2010 Male patient from UNITED STATES , 19 years of age, was diagnosed with acute myeloid leukaemia and was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: aspergillus test positive, haemoptysis, lung infiltration, neutropenia, pulmonary vascular disorder, zygomycosis. Cytarabine dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ). Patient was hospitalized.

6759490-1 | Acute Myeloid Leukaemia, Bone Marrow Transplant, Chronic Graft Versus Host Disease, Immunosuppression, Neoplasm Skin, Oesophageal Squamous Cell Carcinoma, Porokeratosis, Stem Cell Transplant
Patient was taking Cytarabine (View Usage). Patient had the following side effects: acute myeloid leukaemia, bone marrow transplant (What is bone marrow transplant?), chronic graft versus host disease, immunosuppression, neoplasm skin, oesophageal squamous cell carcinoma, porokeratosis, stem cell transplant on May 25, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 32 years of age, was diagnosed with acute myeloid leukaemia, metastasis and. Cytarabine dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), (BLEOMYCIN) (View (bleomycin) Review and (bleomycin) Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ).

6757681-7 | Clostridium Difficile Colitis, Hepatic Steatosis, Pyrexia, Sinus Tachycardia
Adverse event was reported on Jun 04, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 741 Mg) . Location: UNITED STATES , weighting 169.3 lb, After Cytarabine was administered, patient had the following side effects: clostridium difficile colitis, hepatic steatosis, pyrexia, sinus tachycardia. During the same period patient was treated with MERCAPTOPURINE (950 Mg) (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (30 Mg) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (1970 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6757680-5 | Cellulitis, Lung Infiltration, Medical Device Site Reaction, Multi-organ Failure, Neutropenia, Nodule, Pericardial Effusion, Rash Erythematous
on Jun 04, 2010 Male patient from UNITED STATES , weighting 220.5 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: cellulitis (What is cellulitis?), lung infiltration, medical device site reaction, multi-organ failure, neutropenia, nodule, pericardial effusion, rash erythematous. Cytarabine dosage: 4570 Mg. During the same period patient was treated with DAUNORUBICIN HCL (336 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (1125 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6752764-X | Acute Respiratory Distress Syndrome, Chest Pain, Infection, Pulmonary Alveolar Haemorrhage, Pulmonary Toxicity, Pyrexia
on Jun 02, 2010 Female patient from UNITED STATES , weighting 236.1 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: acute respiratory distress syndrome, chest pain (What is chest pain?), infection (What is infection?), pulmonary alveolar haemorrhage, pulmonary toxicity, pyrexia. Cytarabine dosage: 1512 Mg. During the same period patient was treated with DAUNORUBICIN HCL (372 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (648 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6745651-4 | Febrile Neutropenia, Pulmonary Mass, Rash
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: febrile neutropenia, pulmonary mass, rash (What is rash?) on Apr 21, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 41 years of age, . Cytarabine dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), (DASATINIB) (140 Mg Milligram(s)) (View (dasatinib) Review and (dasatinib) Label ), (FILGRASTIM) (View (filgrastim) Review and (filgrastim) Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), IMATINIB MESILATE (View Imatinib Mesilate Review and Imatinib Mesilate Label ). Patient was hospitalized.

6738940-0 | Ear Infection, Hearing Impaired, Hypertensive Crisis, Pulmonary Oedema
Adverse event was reported on Mar 25, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 39.6 Mg, 1 Day, Subcutaneous ; 37.8 Mg , 1 Day, Subcutaneous) was diagnosed with acute myeloid leukaemia and. Location: UNITED STATES , 81 years of age, Patient experienced the following unwanted or unexpected effects: ear infection (What is ear infection?), hearing impaired, hypertensive crisis, pulmonary oedema. During the same period patient was treated with (HYDROXYCARBAMIDE) (View (hydroxycarbamide) Review and (hydroxycarbamide) Label ), ZOFRAN (View Zofran Review and Zofran Label ), SODIUM CHLORIDE 0.9% INJECTION, USP, IN FLEXIBLE CONTAINERS (View Sodium Chloride 0.9% Injection, Usp, In Flexible Containers Review and Sodium Chloride 0.9% Injection, Usp, In Flexible Containers Label ), POTASSIUM CHLORIDE FOR INJ, USP (POTASSIUM CHLORIDE) (View Potassium Chloride For Inj, Usp (potassium Chloride) Review and Potassium Chloride For Inj, Usp (potassium Chloride) Label ), CAPTOPRIL (View Captopril Review and Captopril Label ), (METOCARD) (View (metocard) Review and (metocard) Label ), (ENARENAL) (View (enarenal) Review and (enarenal) Label ). Patient was hospitalized.

6736883-X | Diarrhoea, Epistaxis, Febrile Neutropenia, Haematocrit Decreased, Haemoglobin Decreased, Laboratory Test Interference, Mouth Ulceration, Platelet Count Decreased, Pneumonia
on May 20, 2010 Male patient from UNITED STATES , weighting 235.9 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: diarrhoea, epistaxis, febrile neutropenia, haematocrit decreased, haemoglobin decreased, laboratory test interference, mouth ulceration, platelet count decreased, pneumonia (What is pneumonia?). Cytarabine dosage: 38.24 G. During the same period patient was treated with ETOPOSIDE (3620 Mg) (View Etoposide Review and Etoposide Label ), G CSF (FILGRASTIM, AMGEN) (960 Mcg) (View G-csf (filgrastim, Amgen) Review and G-csf (filgrastim, Amgen) Label ). Patient was hospitalized.

6736879-8 | Acute Respiratory Distress Syndrome, Chest Pain, Infection, Pulmonary Alveolar Haemorrhage, Pulmonary Toxicity, Pyrexia
on May 20, 2010 Female patient from UNITED STATES , weighting 236.1 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: acute respiratory distress syndrome, chest pain (What is chest pain?), infection (What is infection?), pulmonary alveolar haemorrhage, pulmonary toxicity, pyrexia. Cytarabine dosage: 1512. During the same period patient was treated with DAUNORUBICIN HCL (372 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (648 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6731419-1 | Ammonia Increased, Confusional State, Continuous Haemodiafiltration, Depressed Level Of Consciousness, Haemodialysis, Pancytopenia, Transaminases Increased
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: ammonia increased, confusional state, continuous haemodiafiltration, depressed level of consciousness, haemodialysis, pancytopenia, transaminases increased on May 18, 2010 from CANADA Additional patient health information: Female patient , weighting 127.0 lb, . Cytarabine dosage: 13670 Mg. During the same period patient was treated with MYLOTARG (5 Mg) (View Mylotarg Review and Mylotarg Label ), MITOXANTRONE HYDROCHLORIDE (80 Mg) (View Mitoxantrone Hydrochloride Review and Mitoxantrone Hydrochloride Label ), ATIVAN (View Ativan Review and Ativan Label ), CARBOGLU (View Carboglu Review and Carboglu Label ), DOXYCYCINE (View Doxycycine Review and Doxycycine Label ), FLAGYL (View Flagyl Review and Flagyl Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), HYDROMORPHONE HCL (View Hydromorphone Hcl Review and Hydromorphone Hcl Label ). Patient was hospitalized.

6728520-5 | Febrile Neutropenia, Pulmonary Mass, Rash
Adverse event was reported on May 17, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: ) . Location: UNITED KINGDOM , 41 years of age, Patient had the following side effects: febrile neutropenia, pulmonary mass, rash (What is rash?). During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), DASATINIB (140 Mg, 1x/day) (View Dasatinib Review and Dasatinib Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), FILGRASTIM (View Filgrastim Review and Filgrastim Label ), IMATINIB MESILATE (View Imatinib Mesilate Review and Imatinib Mesilate Label ). Patient was hospitalized.

6727638-0 | Febrile Neutropenia, Pulmonary Mass, Rash
on Apr 28, 2010 Female patient from UNITED KINGDOM , 41 years of age, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: febrile neutropenia, pulmonary mass, rash (What is rash?). Cytarabine dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), DASATINIB (140mg Milligram(s)) (View Dasatinib Review and Dasatinib Label ), FILGRASTIM (View Filgrastim Review and Filgrastim Label ). Patient was hospitalized.

6715777-X | Febrile Neutropenia, Pulmonary Mass, Rash
on Apr 28, 2010 Female patient from UNITED KINGDOM , 41 years of age, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, pulmonary mass, rash (What is rash?). Cytarabine dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), DASATINIB (140 Mg, 1x/day) (View Dasatinib Review and Dasatinib Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), FILGRASTIM (View Filgrastim Review and Filgrastim Label ), IMATINIB MESILATE (View Imatinib Mesilate Review and Imatinib Mesilate Label ). Patient was hospitalized.

6714120-X | Acute Abdomen, Atelectasis, Atrial Fibrillation, Clostridium Bacteraemia, Colitis, Diverticulitis, Enterocolitis, Escherichia Bacteraemia, Neutropenic Colitis
Patient was taking Cytarabine (View Usage). Patient had the following side effects: acute abdomen, atelectasis, atrial fibrillation (What is atrial fibrillation?), clostridium bacteraemia, colitis, diverticulitis, enterocolitis, escherichia bacteraemia, neutropenic colitis on Apr 21, 2010 from CANADA Additional patient health information: Male patient , 59 years of age, weighting 154.3 lb, was diagnosed with acute myeloid leukaemia and. Cytarabine dosage: . During the same period patient was treated with VORTICONAZOLE (View Vorticonazole Review and Vorticonazole Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), TOBRAMYCIN (View Tobramycin Review and Tobramycin Label ), VANCOMYCIN HCL INJ (View Vancomycin Hcl Inj Review and Vancomycin Hcl Inj Label ), ACYCLOVIR SODIUM (View Acyclovir Sodium Review and Acyclovir Sodium Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), AMOXICILLIN (View Amoxicillin Review and Amoxicillin Label ). Patient was hospitalized.

6713287-7 | Back Pain, Pyrexia
Adverse event was reported on May 05, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: 34560 Mg) . Location: UNITED STATES , weighting 180.3 lb, After Cytarabine was administered, patient had the following side effects: back pain (What is back pain?), pyrexia. Patient was hospitalized.

6713272-5 | Anorectal Cellulitis, Chest Pain, Neutropenia, Pruritus, Rash Erythematous, Staphylococcal Infection
on May 05, 2010 Female patient from UNITED STATES , weighting 174.6 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: anorectal cellulitis, chest pain (What is chest pain?), neutropenia, pruritus, rash erythematous, staphylococcal infection (What is staphylococcal infection?). Cytarabine dosage: 34020 Mg. Patient was hospitalized.

6712737-X | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Cells In Urine, Chills, Dehydration, Diarrhoea Infectious, Faeces Discoloured
on May 06, 2010 Female patient from UNITED STATES , weighting 215.2 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, cells in urine, chills, dehydration, diarrhoea infectious, faeces discoloured. Cytarabine dosage: 1512 Mg. During the same period patient was treated with DAUNORUBICIN HCL (582 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (648 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

6710390-2 | Bone Marrow Transplant, Febrile Neutropenia, Pulmonary Mass, Rash
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: bone marrow transplant (What is bone marrow transplant?), febrile neutropenia, pulmonary mass, rash (What is rash?) on Apr 21, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 41 years of age, . Cytarabine dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), (DASATINIB) (140 Mg Milligram(s)) (View (dasatinib) Review and (dasatinib) Label ), (FILGRASTIM) (View (filgrastim) Review and (filgrastim) Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), (IMATINIB MESILATE) (View (imatinib Mesilate) Review and (imatinib Mesilate) Label ). Patient was hospitalized.

6706930-X | Hepatic Failure
Adverse event was reported on Apr 21, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 170 Mg, 1x/day) was diagnosed with acute myeloid leukaemia, prophylaxis, hypothyroidism, fluid retention and. Location: SPAIN , 65 years of age, weighting 141.1 lb, Patient experienced the following unwanted or unexpected effects: hepatic failure. During the same period patient was treated with IDARUBICIN HCL (20 Mg, 1x/day) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), MYLOTARG (5 Mg, 1x/day) (View Mylotarg Review and Mylotarg Label ), ALMAGATE (4.5 G, 1x/day) (View Almagate Review and Almagate Label ), OMEPRAZOLE (20 Mg, 1x/day) (View Omeprazole Review and Omeprazole Label ), LEVOTHYROXINE SODIUM (50 Ug, 1x/day) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), LEVOFLOXACIN (500 Mg, 1x/day) (View Levofloxacin Review and Levofloxacin Label ), SEGURIL (250 Mg, 1x/day) (View Seguril Review and Seguril Label ), CLEXANE (40 Mg, 1x/day) (View Clexane Review and Clexane Label ).

6706651-3 | Aspergillosis, Febrile Neutropenia, Haemorrhage, Hallucination, Visual, Pneumonia, Staphylococcal Infection
on Apr 30, 2010 Male patient from UNITED STATES , weighting 216.1 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: aspergillosis, febrile neutropenia, haemorrhage, hallucination, visual, pneumonia (What is pneumonia?), staphylococcal infection (What is staphylococcal infection?). Cytarabine dosage: 38700 Mg. Patient was hospitalized.

6706252-7 | Febrile Neutropenia, Pulmonary Mass, Rash
on Apr 21, 2010 Female patient from UNITED KINGDOM , 41 years of age, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: febrile neutropenia, pulmonary mass, rash (What is rash?). Cytarabine dosage: . During the same period patient was treated with IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ), DASATINIB (140 Mg, 1x/day) (View Dasatinib Review and Dasatinib Label ), FLUDARABINE (View Fludarabine Review and Fludarabine Label ), FILGRASTIM (View Filgrastim Review and Filgrastim Label ), IMATINIB MESILATE (View Imatinib Mesilate Review and Imatinib Mesilate Label ). Patient was hospitalized.

6706220-5 | Fungal Infection, Implant Site Pain, Nausea, Pulmonary Necrosis, Pulmonary Oedema
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: fungal infection (What is fungal infection?), implant site pain, nausea (What is nausea?), pulmonary necrosis, pulmonary oedema on Apr 30, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 218.3 lb, . Cytarabine dosage: 37620 Mg. Patient was hospitalized.

6706219-9 | Bronchopulmonary Aspergillosis
Adverse event was reported on Apr 30, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 1190 Mg) . Location: UNITED STATES , weighting 134.5 lb, Patient had the following side effects: bronchopulmonary aspergillosis. During the same period patient was treated with DAUNORUBICIN HCL (450 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6706205-9 | Abdominal Pain, Acute Respiratory Distress Syndrome, Chills, Diarrhoea, Dizziness, Fluid Overload, Haemoptysis, Leukaemic Infiltration, Pneumonia
on Apr 30, 2010 Female patient from UNITED STATES , weighting 148.6 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), acute respiratory distress syndrome, chills, diarrhoea, dizziness (What is dizziness?), fluid overload, haemoptysis, leukaemic infiltration, pneumonia (What is pneumonia?). Cytarabine dosage: 173 Mg. During the same period patient was treated with DAUNORUBICIN HCL (155 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ETOPOSIDE (519 Mg) (View Etoposide Review and Etoposide Label ), IV HYDRATION AND TRANSFUSION SUPPORT (View Iv Hydration And Transfusion Support Review and Iv Hydration And Transfusion Support Label ). Patient was hospitalized.

6706203-5 | Febrile Neutropenia, White Blood Cell Count Decreased
on Apr 30, 2010 Male patient from UNITED STATES , weighting 197.1 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, white blood cell count decreased. Cytarabine dosage: 38700 Mg. During the same period patient was treated with ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), AVELOX (View Avelox Review and Avelox Label ), POSACONAZOLE (View Posaconazole Review and Posaconazole Label ). Patient was hospitalized.

6706187-X | Abdominal Pain, Blood Creatinine Increased, Blood Culture Positive, Cardio-respiratory Arrest, Chills, Faecal Volume Increased, Hypotension, Irritability, Pseudomonas Infection
Patient was taking Cytarabine (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), blood creatinine increased, blood culture positive, cardio-respiratory arrest, chills, faecal volume increased, hypotension, irritability, pseudomonas infection on Apr 30, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 44.97 lb, . Cytarabine dosage: 70 Mg. During the same period patient was treated with DEXAMETHASONE (67.5 Mg) (View Dexamethasone Review and Dexamethasone Label ), METHOTREXATE (12 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARIGINASE (PEGASPARAGASE, ONCOSPAR) (1875 Iu) (View Peg-l-aspariginase (pegasparagase, Oncospar) Review and Peg-l-aspariginase (pegasparagase, Oncospar) Label ), VINCRISTINE SULFATE (3.3 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6706137-6 | Blood Pressure Diastolic Increased, Catheter Site Related Reaction, Febrile Neutropenia, Feeling Cold, Heart Rate Increased, Induration, Thrombocytopenia, White Blood Cell Count Decreased
Adverse event was reported on Apr 30, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: 38160 Mg) . Location: UNITED STATES , weighting 238.1 lb, After Cytarabine was administered, patient had the following side effects: blood pressure diastolic increased, catheter site related reaction, febrile neutropenia, feeling cold, heart rate increased, induration, thrombocytopenia, white blood cell count decreased. Patient was hospitalized.

6706130-3 | Back Pain, Chills, Haemoglobin Decreased, Nasal Congestion, Nausea, Neutropenia, Oropharyngeal Pain, Platelet Count Decreased, Pyrexia
on Apr 30, 2010 Female patient from UNITED STATES , weighting 240.7 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), chills, haemoglobin decreased, nasal congestion, nausea (What is nausea?), neutropenia, oropharyngeal pain, platelet count decreased, pyrexia. Cytarabine dosage: 38160 Mg. Patient was hospitalized.

6706129-7 | Blood Creatinine Increased, Blood Culture Positive, Chills, Febrile Neutropenia, Pneumonia Fungal, Staphylococcal Infection
on Apr 30, 2010 Male patient from UNITED STATES , weighting 218.3 lb, was treated with Cytarabine (View Usage). Patient had the following side effects: blood creatinine increased, blood culture positive, chills, febrile neutropenia, pneumonia fungal, staphylococcal infection (What is staphylococcal infection?). Cytarabine dosage: 37800 Mg. During the same period patient was treated with ABELCET (View Abelcet Review and Abelcet Label ). Patient was hospitalized.

6702963-8 | Neutropenia, Pyrexia
Patient was taking Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: neutropenia, pyrexia on Apr 29, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 63.27 lb, . Cytarabine dosage: 6300 Mg. During the same period patient was treated with MITOXANTRONE HYDROCHLORIDE (20 Mg) (View Mitoxantrone Hydrochloride Review and Mitoxantrone Hydrochloride Label ), TRETINOIN (420 Mg) (View Tretinoin Review and Tretinoin Label ). Patient was hospitalized.

6702911-0 | Febrile Neutropenia
Adverse event was reported on Apr 29, 2010 by a Female patient taking Cytarabine (View Usage) (Dosage: 1260 Mg) . Location: UNITED STATES , weighting 158.7 lb, Patient experienced the following unwanted or unexpected effects: febrile neutropenia. During the same period patient was treated with DAUNORUBICIN HCL (240 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.

6698607-4 | Cerebral Venous Thrombosis, Headache
on Apr 19, 2010 Female patient from FRANCE , 25 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Cytarabine (View Usage). Patient had the following side effects: cerebral venous thrombosis, headache (What is headache?). Cytarabine dosage: 40 Mg, 1x/day. During the same period patient was treated with METHOTREXATE (15 Mg, 1x/day) (View Methotrexate Review and Methotrexate Label ), DOXORUBICIN HCL (50 Mg/m2, 1x/day) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DEPO MEDROL (15 Mg, 1x/day) (View Depo-medrol Review and Depo-medrol Label ), MABTHERA (750 Mg, 1x/day) (View Mabthera Review and Mabthera Label ), ENDOXAN (1.5 Mg, 1x/day) (View Endoxan Review and Endoxan Label ), VINCRISTINE (2 Mg, 1x/day) (View Vincristine Review and Vincristine Label ), CORTANCYL (Unk) (View Cortancyl Review and Cortancyl Label ), NEXIUM (Unk) (View Nexium Review and Nexium Label ). Patient was hospitalized.

6695461-1 | Anaemia, Blood Pressure Diastolic Decreased, Confusional State, Platelet Count Decreased, Syncope
on Apr 22, 2010 Female patient from UNITED STATES , 87 years of age, weighting 113.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: anaemia, blood pressure diastolic decreased, confusional state, platelet count decreased, syncope. Cytarabine dosage: 31.2 Mg Sc. During the same period patient was treated with G CSF 300 MG DAY 1 5 EVERY 28D (300 Mg Sc) (View G-csf 300 Mg Day 1-5 Every 28d Review and G-csf 300 Mg Day 1-5 Every 28d Label ), DACITABINE 20 MG/M2 DAY 1 5 EVERY 28 DAYS (31.2 Mg Iv Daily D1-5) (View Dacitabine 20 Mg/m2 Day 1-5 Every 28 Days Review and Dacitabine 20 Mg/m2 Day 1-5 Every 28 Days Label ), DACITABINE 20 MG/M2 DAY 1 5 EVERY 28 DAYS (31.2 Mg Iv Daily D1-5) (View Dacitabine 20 Mg/m2 Day 1-5 Every 28 Days Review and Dacitabine 20 Mg/m2 Day 1-5 Every 28 Days Label ), PROPRANOLOL (View Propranolol Review and Propranolol Label ), PRILOSEC (View Prilosec Review and Prilosec Label ), REGLAN (View Reglan Review and Reglan Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), VORICONAZOLE (View Voriconazole Review and Voriconazole Label ). Patient was hospitalized.

6694422-6 | Anaemia, Asthenia, Atrial Fibrillation, Cardiovascular Disorder, Dehydration, Disorientation, Hypertension, Left Ventricular Hypertrophy, Mental Status Changes
Patient was taking Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, asthenia, atrial fibrillation (What is atrial fibrillation?), cardiovascular disorder, dehydration, disorientation, hypertension, left ventricular hypertrophy, mental status changes on Apr 14, 2010 from UNITED STATES Additional patient health information: Male patient , 74 years of age, was diagnosed with acute myeloid leukaemia and. Cytarabine dosage: 20 Mg/m2, Subcutaneous. During the same period patient was treated with KLOR CON (View Klor-con Review and Klor-con Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), (LISINOPRIL) (View (lisinopril) Review and (lisinopril) Label ), ACTOS (View Actos Review and Actos Label ), PAXIL (View Paxil Review and Paxil Label ), KEPPRA (View Keppra Review and Keppra Label ). Patient was hospitalized.

6687574-5 | Depression, Weight Decreased, Weight Gain Poor
Adverse event was reported on Apr 16, 2010 by a Male patient taking Cytarabine (View Usage) (Dosage: 70 Mg) . Location: UNITED STATES , weighting 96.56 lb, Patient had the following side effects: depression (What is depression?), weight decreased, weight gain poor. During the same period patient was treated with DAUNORUBICIN HCL (172 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (30 Mg) (View Methotrexate Review and Methotrexate Label ), PREDNISONE (1400 Mg) (View Prednisone Review and Prednisone Label ), VINCRISTINE SULFATE (8 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6687573-3 | Bacillus Infection, Bacterial Infection, Bacterial Test Positive, Device Related Infection, Enterococcal Infection, Immunosuppression, Respiratory Failure, Respiratory Syncytial Virus Infection, Respiratory Tract Infection Bacterial
on Apr 16, 2010 Male patient from UNITED STATES , weighting 37.04 lb, was treated with Cytarabine (View Usage). After Cytarabine was administered, patient had the following side effects: bacillus infection, bacterial infection (What is bacterial infection?), bacterial test positive, device related infection, enterococcal infection, immunosuppression, respiratory failure, respiratory syncytial virus infection (What is respiratory syncytial virus infection?), respiratory tract infection bacterial. Cytarabine dosage: 70 Mg. During the same period patient was treated with DAUNORUBICIN HCL (52.3 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), METHOTREXATE (12 Mg) (View Methotrexate Review and Methotrexate Label ), PEG L ASPARAGINASE (K H) (1720 Mg) (View Peg-l Asparaginase (k-h) Review and Peg-l Asparaginase (k-h) Label ), PREDNISONE (990 Mg) (View Prednisone Review and Prednisone Label ), VINCRISTINE SULFATE (4.3 Mg) (View Vincristine Sulfate Review and Vincristine Sulfate Label ). Patient was hospitalized.

6687213-3 | Bacterial Infection, Blood Culture Positive, Cardiac Arrest, Cerebral Ventricle Dilatation, Clostridium Difficile Colitis, Complex Partial Seizures, Coordination Abnormal, Dysarthria, Electromechanical Dissociation
on Apr 16, 2010 Male patient from UNITED STATES , weighting 145.1 lb, was treated with Cytarabine (View Usage). Patient experienced the following unwanted or unexpected effects: bacterial infection (What is bacterial infection?), blood culture positive, cardiac arrest (What is cardiac arrest?), cerebral ventricle dilatation, clostridium difficile colitis, complex partial seizures, coordination abnormal, dysarthria, electromechanical dissociation. Cytarabine dosage: 28480 Mg. During the same period patient was treated with ETOPOSIDE (2716 Mg) (View Etoposide Review and Etoposide Label ), RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (1330 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ). Patient was hospitalized.

6685847-3 | Bronchopulmonary Aspergillosis
Patient was taking Cytarabine (View Usage). Patient had the following side effects: bronchopulmonary aspergillosis on Apr 15, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 134.5 lb, . Cytarabine dosage: 1190 Mg. During the same period patient was treated with DAUNORUBICIN HCL (450 Mg) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ). Patient was hospitalized.